Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Opthea Limited
Opthea to Receive US$35M Commitment and Additional US$50M Funding
December 27, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Receives A$8.8 million R&D Tax Incentive
December 19, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at the FLORetina 2023 Congress
December 01, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at the Jefferies 2023 London Healthcare Conference
November 09, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
October 30, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
October 27, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Participate at the 2023 Euretina Congress
October 02, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
August 28, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
July 26, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at the 2023 Ophthalmology Innovation Summit
July 24, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
July 13, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
July 10, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
June 08, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at the Jefferies 2023 Healthcare Conference
May 25, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
May 17, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea To Present at the JMP Securities Life Sciences Conference
May 08, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
April 28, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Receives A$8.7 million R&D Tax Incentive
March 07, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
March 06, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
February 13, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea To Present at SVB Leerink Global Biopharma Conference
February 06, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea To Present at Sequire Biotechnology Conference
January 30, 2023
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
December 12, 2022
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at the FLORetina 2022 Congress
December 06, 2022
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea to Present at Jefferies London Healthcare Conference
November 10, 2022
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
October 24, 2022
From
Opthea Limited
Via
GlobeNewswire
Tickers
ASX:OPT
OPT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.